Pocket Profile for BioPersMed (Biomarkers of Personalized Medicine)
Graz: a mono-center, long-term, observational, prospective cohort study to evaluate novel biomarkers for the assessment of cardiovascular and metabolic diseases and related complications

Authors: Haudum CW¹, Kolesnik E², Colantonio C³, Mursic I¹, Url-Michitsch M³, Tomaschitz A³, Glantschnig T², Hutz B¹, Lind A¹, Schweighofer N³, Reiter C⁴, Verheyen N³, Ablasser K⁵, Wallner M³, Tripolt N.¹, Pieske-Kraigher E⁵, Madl T⁶, Seidel G⁷, Wedrich A⁷, Zirlik A³, Krahn T⁸, Stuber R³, Pieske B⁵, Pieber T¹, Obermayer-Pietsch B¹⁰, Schmidt A³⁹

Cite this as: The full version of this profile is available at IJE online and should be used when citing this profile.

Corresponding Authors: Barbara Obermayer-Pietsch (barbara.obermayer@medunigraz.at) & Albrecht Schmidt (albrecht.schmidt@medunigraz.at)

Key Words: cardiovascular, endocrine and metabolic biomarkers, cohort study

Cohort Purpose: In the BioPersMed Study (Biomarkers of Personalized Medicine), we enrolled community dwelling and asymptomatic patients at risk for cardiovascular disease in order to evaluate the predictive value of various biomarkers reflecting different pathways of cardiovascular and metabolic disease development. The aim is to evaluate large-scale screening tools for the improvement of cardiovascular and metabolic risk stratification, early diagnosis, prediction of clinical outcomes, and long-term clinical monitoring of patients at cardiovascular risk.

Cohort Basics: Centred at the city of Graz (Styria, Austria), baseline data collection between 2010 and 2016 resulted in the initial recruitment of 1024 patients at the age of 45 years or older presenting with at least one classic cardiovascular risk factor or manifest diabetes mellitus type 2 at the age of 18 years or older.

Follow-up and Attrition: Follow-up includes a telephone visit every odd year after enrollment and a full clinical phenotyping every even year after enrollment. Until now, 799 patients completed the first clinical follow-up and 595 patients have attended the second clinical follow-up. A few patients skipped either the first or second clinical follow-up but are continuing the study. So far (1st March 2020), 169 probands will not be available for future follow-ups (drop-outs).
**Design and Measures:** The BioPersMed project is designed as a single-centre, prospective, observational study. At baseline and at regular 2 years-follow-ups, an in-depth diagnostic work-up is carried out including: questionnaires (for health, past medical history, psychosocial and sleep issues), physical examination, ECG, lab/blood sampling with biobanking (including a broad hormonal and metabolic characterisation), exercise testing (6min walking test, grip strength, spiroergometry), echocardiography, pulmonary function testing, carotid intima/media-thickness measurement, pulse-wave analysis, ophthalmologic examinations, body composition assessment, bone density quantification and oral glucose tolerance tests.
**Unique Features:** The variety of assessed biomarkers allow a comprehensive phenotyping of patients at cardiovascular risk, thereby opening up the possibility to reveal connections between different biomarkers of different organ systems and diseases. This information may serve as a basis for a multi-disciplinary in-depth analysis and cooperation with other prospective cohorts (e.g. with an interventional design).

**Reasons to be Cautious:** Firstly, a potential weakness of this study is the time range of a rather slow recruitment due to logistic reasons between 2010 and 2016. This results in a prolonged follow-up period of study participants between 4 and 10 years. Secondly, after a thorough standardized baseline phenotyping, the characterization of the BioPersMed cohort has been expanded by additional diagnostic tools at later timepoints (e.g. non-mydriatic funduscopy). Although some of these biomarkers are not available for the complete duration of the entire cohort, cross-sectional analysis of a considerable number of probands can already be performed with these data sets and will be available for longitudinal comparison of follow-up visits thereafter.

**Collaboration and Data Access:** The design of the BioPersMed study, data management, biobanking and data analyses are compliant to the STROBE, STROBE-ME and STREGA recommendations. Collaboration in data analysis and publications will be welcome through specific research proposals sent to the BioPersMed investigators listed as corresponding authors.

**Funding and Competing Interests:** Austrian Federal Ministry of Transport, Innovation and Technology (BMVIT); Austrian Federal Ministry of Economics and Labour/the Federal Ministry of Economy, Family and Youth (BMWA/BMWFJ); unrestricted research grant from Bayer AG. The authors declare no conflict of interest.

**Author Affiliations:** ¹Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria; ²Division of Cardiology, Medical University of Graz, Graz, Austria; ³Department of Radiology, Medical University of Graz, Graz, Austria; ⁴Department of Internal Medicine and Cardiology, Charité University Medicine, Campus Virchow Klinikum and German Heart Center, Berlin, Germany; ⁵Gottfried Schatz Research Center, Chair of Molecular Biology and Biochemistry, Medical University of Graz, Graz, Austria; ⁶Department of Ophthalmology, Medical University of Graz, Graz, Austria; ⁷Division of Gastroenterology and Hepatology, Medical University of Graz, Graz, Austria